biovariance pharma patents in biological pathways

7/31/2019 BioVariance Pharma Patents in Biological Pathways

1/15

BioVariance Research Services

Josef Scheiber, PhDwww.biovariance.com
http://www.biovariance.com/http://www.biovariance.com/


2/15

BioVariance - Overview

Two distinct offerings rooted in the same data:

Medical value content-as-a-Service for Healthcare

Bio-Variance

BaVarians ;)


3/15

Overview

Background

Analysis approach

Example Outlook


4/15

Background

Patents hold a significant amount of recent,highly relevant information

Question to answer: What targets do my

competitors publish patents for? What indicationare they working on for a particular target?

How can I use this for my efforts?

We aim for that areby data from scientific databases andthe literature


5/15

Recent competitor patents provideplenty of relevant knowledge

Patent


6/15

Leveraging competitor information forbetter drug understanding


7/15

General workflow

Patents published

in 2011

Standard identifiers for basic content


8/15

General workflow

Patents published

in 2011Patents published

in 2011


9/15

Statistics of targets in patents

Pharma A 41 unique ID Targets, 7 of them with several patent Pharma B 36 unique ID Targets, 16 of them with several patents

(Q9UBL9; P04150; P30559;P07550; P10275; Q9Y5N1)

A BPharma A (2010) Pharma B (2011)

Total patents published (for specified year) 83 103

Relevant patents 75 76

35

6

30


10/15

Comparison of indicationson target-level

P04150Treatment of inflammation and/or allergic conditions., Treatment of

inflammatory and/or allergic conditions.

Treatment of inflammation related condition (e.g. asthma,

rheumatoid arthritis, dermatitis, inflammatory bowel disease,

transplant rejection, multiple sclerosis, chronic uveitis, or chronic

obstructive pulmonary disease); mitigating bone loss associated with

prednisolone treatment., Treatment of inflammation related condition

(e.g. asthma, rheumatoid arthritis, dermatitis, inflammatory bowel

disease, transplant rejection, multiple sclerosis, chronic uveitis, or

chronic obstructive pulmonary disease); mitigating bone lossassociated with prednisolone treatment.

P07550

Treatment of pulmonary disorders, e.g. chronic obstructive

pulmonary disease (COPD) and asthma., Treatment and prophylaxis of

diseases associated with reversible airways obstruction such as

asthma, chronic obstructive pulmonary diseases (COPD) (e.g. chronic

and wheezy bronchitis, emphysema), respiratory tract infection and

upper respiratory tract disease (e.g. rhinitis, including seasonal and

allergic rhinitis), premature labour, depression, congestive heart

failure, skin diseases (e.g. inflammatory, allergic, psoriatic, and

proliferative skin diseases), conditions where lowering peptic acidity

is desirable (e.g. peptic and gastric ulceration) and muscle wasting

disease.

Treatment of premature labor, congestive heart failure, depression,

inflammatory and allergic skin diseases, psoriasis, proliferative skin

diseases, glaucoma and in conditions where there is an advantage in

lowering gastric acidity, particularly in gastric and peptic ulceration,

chronic bronchitis and emphysema., Treatment of premature labor,

congestive heart failure, depression, inflammatory and allergic skin

diseases, psoriasis, proliferative skin diseases, glaucoma and inconditions where there is an advantage in lowering gastric acidity,

particularly in gastric and peptic ulceration, chronic bronchitis and

emphysema.

Opportunity?


11/15

Mapping into biological Pathways(here: Nature Pathway Interaction Database)

Automated mapping of targetidentifiers into biological

pathways, each target can be a

member of several pathways

(exemplified with T2), thereby

one can link annotations from

competitor patents (likeindication) to the pathways of

own projects

Also a combined visualization is

possible


12/15

Mapping into biological Pathways(here: Nature Pathway Interaction Database)

Pharma A: 41 unique IDs map into 116 Pathways, 64 of them with severaltargets (40% of pathways worked on covered by competitor)

Pharma B: 36 unique ID Targets map into 77 Pathways, 32 of these withseveral targets (61% of pathways worked on covered by competitor)

47 Pathways where both have patents (see next slide for example)

A B

69

47

30


13/15

(in total 47 matching pathways)Pathway Indication Patent Company A Indication Patent Company B

angiopoietinreceptor_pathway

Treatment of rheumatoid arthritis, osteoarthritis, meningitis,

ischemic and hemorrhagic stroke, neurotrauma/closed head

injury, stroke, endotoxemia and/or toxic shock syndrome,

other acute or chronic inflammatory disease states such as

the inflammatory reaction induced by endotoxin or

inflammatory bowel disease, tuberculosis, atherosclerosis,

muscle degeneration, multiple sclerosis, cachexia, bone

resorption, psoriatic arthritis, Reiter's syndrome, gout,

traumatic arthritis, rubella arthritis and acute synovitis.

Treatment of cancer.

ap1_pathway Treatment of inflammation and/or allergic conditions.,

Treatment of inflammatory disorders, autoimmune disorders (e.g., lupus), skin-

inflammatory disorders, intestinal inflammatory disorders, asthma and atopic

disorders, and transplant graft rejection, neurological disorders or complications

due to stroke or head injury, benign or malignant neoplastic disease, carcinomas

and adenocarcinoma and proliferative disorders., Treatment of inflammation

related condition (e.g. asthma, rheumatoid arthritis, dermatitis, inflammatory

bowel disease, transplant rejection, multiple sclerosis, chronic uveitis, or chronic

obstructive pulmonary disease); mitigating bone loss associated withprednisolone treatment., Treatment of inflammatory disorders, autoimmune

disorders (e.g., lupus), skin-inflammatory disorders, intestinal inflammatory

disorders, asthma and atopic disorders, and transplant graft rejection,

neurological disorders or complications due to stroke or head injury, benign or

malignant neoplastic disease, carcinomas and adenocarcinoma and proliferative

disorders., Treatment of inflammation related condition (e.g. asthma, rheumatoid

arthritis, dermatitis, inflammatory bowel disease, transplant rejection, multiple

sclerosis, chronic uveitis, or chronic obstructive pulmonary disease); mitigating

bone loss associated with prednisolone treatment.

Opportunity?


14/15

Outlook

We will further work on this!


15/15

[email protected]: +49 89 189 6582 80

Garmischer Str. 4/V

80339 Munich / Germany
mailto:[email protected]:[email protected]

biovariance pharma patents in biological pathways

Documents